Abstract
No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.
| Original language | English |
|---|---|
| Pages (from-to) | 385-393 |
| Number of pages | 9 |
| Journal | Gut and Liver |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2013 Jul 1 |
Fingerprint
Keywords
- Drug therapy
- Stomach neoplasms
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
Chemotherapy for advanced gastric cancer : Review and update of current practices. / Park, Sung Chul; Chun, Hoon-Jai.
In: Gut and Liver, Vol. 7, No. 4, 01.07.2013, p. 385-393.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Chemotherapy for advanced gastric cancer
T2 - Review and update of current practices
AU - Park, Sung Chul
AU - Chun, Hoon-Jai
PY - 2013/7/1
Y1 - 2013/7/1
N2 - No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.
AB - No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.
KW - Drug therapy
KW - Stomach neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84880315269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880315269&partnerID=8YFLogxK
U2 - 10.5009/gnl.2013.7.4.385
DO - 10.5009/gnl.2013.7.4.385
M3 - Review article
VL - 7
SP - 385
EP - 393
JO - Gut and Liver
JF - Gut and Liver
SN - 1976-2283
IS - 4
ER -